Products
Pre-made Brentuximab Vedotin benchmark antibody (Whole mAb ADC, anti-TNFRSF8 therapeutic antibody, Anti-CD30/D1S166E/Ki-1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-765
Pre-made Brentuximab Vedotin benchmark antibody (Whole mAb ADC, anti-TNFRSF8 therapeutic antibody, Anti-CD30/D1S166E/Ki-1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Brentuximab vedotin (INN; trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD3 antigen, a defining marker of Hodgkin lymphoma and ALCL.[2] The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seattle Genetics in the US.[3]
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-765-1mg | 1mg | 4635 | ||
| GMP-Bios-INN-765-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-765-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-765-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Brentuximab Vedotin Biosimilar, Whole Mab Adc, Anti-Tnfrsf8 Antibody: Anti-CD30/D1S166E/Ki-1 therapeutic antibody Drug Conjugate |
| INN Name | Brentuximab Vedotin |
| Target | TNFRSF8 |
| Format | Whole mAb ADC |
| Derivation | Chimeric |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Seattle genetics, Inc. (Bothell WA USA) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
